{"id":39699,"date":"2026-10-06T09:35:00","date_gmt":"2026-10-06T13:35:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=39699"},"modified":"2026-09-24T21:40:04","modified_gmt":"2026-09-25T01:40:04","slug":"if-your-patent-database-cant-answer-what-can-we-do-with-this-it-isnt-strategic-intelligence","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/if-your-patent-database-cant-answer-what-can-we-do-with-this-it-isnt-strategic-intelligence\/","title":{"rendered":"If Your Patent Database Can’t Answer ‘What Can We Do With This?’ It Isn’t Strategic Intelligence"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

On June 4, 2026, the Supreme Court ruled 9-0 that Hikma Pharmaceuticals did not induce patent infringement by selling a skinny-label generic version of Amarin’s Vascepa. Every patent database in the industry had the same underlying facts before that ruling came down: Amarin’s method-of-use patents, Hikma’s FDA-approved carve-out label, the press releases Hikma issued at launch. None of that data told you how the case would come out. The facts didn’t change on June 4. The question of what to do with them did. [1][2]<\/sup><\/p>\n\n\n\n

The Short Answer<\/h2>\n\n\n\n

A commercial patent database is built to answer ‘what exists’: patent numbers, assignees, expiration dates, family size, listing status. It is not built to answer ‘what can we do with this,’ which is a different kind of question involving legal standards, conduct, and litigation posture that shift independently of the underlying patent record. Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.<\/em> is a clean, current illustration: the six Vascepa patents at issue were exactly as listed before and after the ruling. What changed was whether a specific set of marketing conduct crossed a legal line, a question no patent number can answer by itself.<\/p>\n\n\n\n

The Findings That Matter<\/h2>\n\n\n\n
    \n
  • The Supreme Court’s Hikma v. Amarin<\/em> ruling was unanimous, 9-0, authored by Justice Ketanji Brown Jackson, and reversed a 2024 Federal Circuit decision that had let Amarin’s inducement claim proceed. [1][2]<\/sup><\/li>\n\n\n\n
  • The dispute over whether Hikma’s marketing was lawful ran roughly 66 months, from Amarin’s November 30, 2020 complaint to the June 4, 2026 decision, calculated from Amarin’s own SEC filings and the Supreme Court’s opinion date. [7][1]<\/sup><\/li>\n\n\n\n
  • The ruling did not touch patent validity. A separate, earlier proceeding had already invalidated Amarin’s original MARINE-indication patents as obvious in March 2020, a fact the patent record reflected years before the inducement question was resolved. [7]<\/sup><\/li>\n\n\n\n
  • In December 2024, the Federal Circuit affirmed a different kind of database-versus-strategy gap in Teva v. Amneal<\/em>: five of Teva’s ProAir HFA inhaler patents were listed in the Orange Book, and the Federal Circuit ordered them delisted because they claimed device components, not the active ingredient. [10][11]<\/sup><\/li>\n\n\n\n
  • The FTC’s Orange Book warning-letter campaign, launched under a September 2023 policy statement, has grown to roughly 400 challenged patent listings across multiple rounds of letters. [12][13]<\/sup><\/li>\n\n\n\n
  • IQVIA and GlobalData estimate more than $230 billion in US brand-drug revenue is exposed to loss of exclusivity between 2025 and 2030, with up to 65% of large pharmaceutical companies’ current revenue at risk by 2030. [14]<\/sup><\/li>\n\n\n\n
  • Evaluate’s global estimate for the same window exceeds $300 billion, a larger number driven by geographic scope (global versus US-only) rather than by a different read on the underlying trend. [15][16]<\/sup><\/li>\n\n\n\n
  • PhRMA and BIO’s joint amicus brief in Hikma v. Amarin<\/em> warned the Court against granting generics what they called a special immunity from inducement liability, framing the case as a fight over the balance Congress struck in Hatch-Waxman. [5]<\/sup><\/li>\n<\/ul>\n\n\n\n

    What a Patent Database Is Built to Tell You<\/h2>\n\n\n\n

    Every commercial pharmaceutical patent database, including DrugPatentWatch’s own core dataset, is organized around a common set of fields, and those fields are genuinely useful. They just answer a narrower question than most teams treat them as answering.<\/p>\n\n\n\n

    The Six Fields Every Commercial Patent Database Gets Right<\/h3>\n\n\n\n

    Patent number, assignee of record, filing and issue dates, Orange Book or Purple Book listing type, expiration date (including any patent term extension), and patent family size and geographic spread. These fields are factual, verifiable against USPTO and FDA records, and stable until an actual legal event changes them, such as a delisting order or a reassignment.<\/p>\n\n\n\n

    Why Those Fields Used to Be Enough<\/h3>\n\n\n\n

    For a large share of Hatch-Waxman history, the fields above were a reasonable proxy for competitive timing. A compound patent with a known expiration date, absent litigation, was a fair predictor of when generic entry could occur. That proxy has weakened as brand portfolios have layered in method-of-use patents, device patents, and formulation patents whose enforceability depends on facts the database itself does not capture, such as what a competitor’s label says and what its sales force actually tells physicians.<\/p>\n\n\n\n

    The Question the Database Couldn’t Answer: Would Hikma’s Marketing Get It Sued?<\/h2>\n\n\n\n

    Vascepa (icosapent ethyl) is a fish-oil-derived cardiovascular drug that generated roughly $614 million in 2020 revenue for Amarin. [7]<\/sup> By 2020, Amarin held patents covering two distinct things: the original MARINE indication (reducing triglycerides) and a narrower, harder-won indication from the REDUCE-IT trial, covering reduction of cardiovascular risk in patients with elevated triglycerides. Those two indications sat at the center of two separate legal fights that a patent database would have listed side by side without distinguishing their very different trajectories.<\/p>\n\n\n\n

    The Skinny Label, Section viii, and the Carve-Out Amarin Never Accepted<\/h3>\n\n\n\n

    Under Hatch-Waxman’s Section viii carve-out provision, a generic manufacturer can omit a still-patented use from its FDA label while marketing the drug for the brand’s remaining, unpatented uses. Hikma received FDA approval on May 22, 2020 for a generic version of Vascepa covering only the original MARINE indication, explicitly carving out Amarin’s cardiovascular-risk indication. [7][6]<\/sup> Hikma launched on a limited scale in November 2020, and Amarin filed its inducement complaint on November 30, 2020, arguing Hikma’s press releases, AB-rating references, and description of its product as a ‘generic version’ of Vascepa amounted to encouraging doctors to prescribe it for the patented, carved-out use. [7]<\/sup><\/p>\n\n\n\n

    What the Federal Circuit Saw in the Same Facts (2024)<\/h3>\n\n\n\n

    A district court dismissed Amarin’s complaint in January 2022. [8]<\/sup> The Federal Circuit reversed in 2024, holding that Amarin had plausibly alleged induced infringement, reasoning that medical providers could read Hikma’s marketing statements as an invitation to prescribe the drug for the patented use. [1]<\/sup> At that point, a patent analyst pulling the Vascepa file would have seen an appellate court siding with the brand, a live infringement theory, and a database entry showing active litigation risk for any company following Hikma’s marketing playbook.<\/p>\n\n\n\n

    Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. \u2014 the Supreme Court’s Answer<\/h3>\n\n\n\n

    The Supreme Court granted certiorari, heard argument on April 29, 2026, and issued a unanimous opinion on June 4, 2026, reversing the Federal Circuit. [14][1]<\/sup><\/p>\n\n\n\n

    The Holding<\/h4>\n\n\n\n

    Writing for a unanimous Court, Justice Jackson held that Amarin failed to plausibly allege induced infringement under 35 U.S.C. \u00a7 271(b), because ‘the central question is whether Amarin plausibly alleged that Hikma actively encouraged infringing uses, not merely whether doctors could plausibly read the alleged statements as instructions to infringe.’ [15]<\/sup> Ordinary distribution of a generic, lawful equivalence statements, and FDA-required or industry-standard communications, the Court held, are not by themselves enough to support an inducement claim. [4]<\/sup><\/p>\n\n\n\n

    What the Court Ruled Out<\/h4>\n\n\n\n
    \n

    Inducement ‘must be clear to the relevant audience and affirmative.’ [15]<\/sup><\/p>\n<\/blockquote>\n\n\n\n

    That line, from the Court’s own opinion, is the operative test going forward. Ballard Spahr’s 2026 Life Sciences Report reads the decision as requiring brand plaintiffs to point to something more specific than routine marketing: sales scripts, physician-facing materials, payer presentations, or promotional content that explicitly ties the generic product to the still-patented indication. [4]<\/sup><\/p>\n\n\n\n

    Why a Unanimous, Jackson-Authored Opinion Signals More Than a 6-3 Split Would Have<\/h4>\n\n\n\n

    A 9-0 opinion, with no separate concurrences carving out exceptions, gives lower courts and patent counsel a firmer baseline than a narrow majority would. PhRMA and BIO’s joint amicus brief had urged the Court not to hand generics what the brief called ‘a special immunity from inducement liability.’ [5]<\/sup> The unanimous outcome means that argument did not persuade a single justice, which is a different, and for brand strategy purposes more consequential, signal than a split decision resting on one or two swing votes would have sent.<\/p>\n\n\n\n

    Date<\/th>Event<\/th>Source<\/th><\/tr><\/thead>
    March 30, 2020<\/td>D. Nevada invalidates Amarin’s original MARINE-indication patents as obvious<\/td>Amarin 10-K\/10-Q<\/td><\/tr>
    May 22, 2020<\/td>FDA approves Hikma’s generic icosapent ethyl for the MARINE (non-cardiovascular-risk) indication only<\/td>Amarin 10-K<\/td><\/tr>
    November 2020<\/td>Hikma launches its generic on a limited scale<\/td>Amarin 10-K; Hikma press materials<\/td><\/tr>
    November 30, 2020<\/td>Amarin files inducement complaint against Hikma over the carved-out cardiovascular-risk indication<\/td>Amarin 10-K<\/td><\/tr>
    January 4, 2022<\/td>District court grants Hikma’s motion to dismiss<\/td>Amarin SEC filing<\/td><\/tr>
    2024<\/td>Federal Circuit reverses, allows inducement claim to proceed<\/td>AIPLA; SCOTUSblog<\/td><\/tr>
    April 29, 2026<\/td>Supreme Court hears oral argument<\/td>SCOTUSblog<\/td><\/tr>
    June 4, 2026<\/td>Supreme Court reverses 9-0, opinion by Justice Jackson; complaint dismissed<\/td>SCOTUSblog; AIPLA<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Original Calculation: How Long the Uncertainty Actually Lasted<\/h3>\n\n\n\n

    Amarin filed its inducement complaint against Hikma on November 30, 2020. [7]<\/sup> The Supreme Court’s decision issued June 4, 2026. [1]<\/sup> That is approximately 66 months, or roughly five and a half years, during which any company deciding whether to launch a skinny-label competitor to a method-of-use-protected brand drug had no binding answer to the question that mattered most: does marketing a lawful carve-out create infringement exposure. This figure is a calculation from the two filing dates in the primary record, not a reported statistic.<\/p>\n\n\n\n

    The Database Was Right the Whole Time. That’s the Point.<\/h2>\n\n\n\n

    The Patents Are Still There<\/h3>\n\n\n\n

    Nothing about the ruling removed Amarin’s patents from the Orange Book or declared them invalid. The REDUCE-IT-indication method-of-use patents remain on record exactly as they were. A database query on Vascepa run the week before the decision and the week after would return the same patent numbers, the same assignee, and the same listing type.<\/p>\n\n\n\n

    What Changed Wasn’t the Patent Record \u2014 It Was the Legal Standard Applied to Conduct<\/h3>\n\n\n\n

    What changed is a fact no patent field captures: whether a specific company’s marketing language, given the current legal standard, creates enough litigation risk to justify a different launch strategy. That is a conduct-and-precedent question, not a patent-record question, and it is exactly the kind of question ‘what can we do with this’ is built to ask.<\/p>\n\n\n\n

    A Second Case, Same Divide: Is the Patent Even Properly Listed?<\/h2>\n\n\n\n

    Hikma v. Amarin<\/em> is not the only 2026-relevant example of the gap between a patent record and an actionable answer. A second, structurally different question sits in the Orange Book listing process itself: not whether a patent is enforceable against specific conduct, but whether it belongs in the Orange Book at all.<\/p>\n\n\n\n

    Teva v. Amneal and the ‘Claims the Active Ingredient’ Test<\/h3>\n\n\n\n

    Teva listed patents covering components of its ProAir HFA inhaler, including a dose counter, in the Orange Book against its albuterol sulfate product. Amneal counterclaimed that the patents were improperly listed because none of them claimed albuterol sulfate itself, only device components. In December 2024, the Federal Circuit agreed, holding that a patent must claim at least the active ingredient to be properly listed, and that ‘patents claiming just the device components of the product approved in an NDA do not meet the listing requirement.’ [10]<\/sup> The Federal Circuit denied Teva’s request for an en banc rehearing in March 2025. [11]<\/sup><\/p>\n\n\n\n

    The FTC’s Parallel Track<\/h3>\n\n\n\n

    The Federal Circuit’s ruling did not happen in isolation. The FTC had already been building a case that Orange Book device patents like Teva’s created improper 30-month litigation stays, issuing a September 2023 policy statement and following it with rounds of warning letters challenging listings across inhalers, autoinjectors, and other drug-device combinations. [12][13]<\/sup><\/p>\n\n\n\n

    How Many Listings Are Actually in Dispute<\/h4>\n\n\n\n

    The FTC’s letters had challenged over 100 patents in its first round in November 2023, expanded to roughly 300 more in April 2024, and grew the cumulative total to approximately 400 challenged listings by its May 2025 round of seven additional warning letters. [13][12]<\/sup> A database entry showing ‘patent listed, unexpired’ does not distinguish a listing the FTC has already targeted from one it hasn’t looked at.<\/p>\n\n\n\n

    What Delisting Actually Removes<\/h3>\n\n\n\n

    Delisting a patent from the Orange Book does not invalidate it. It removes the patent’s ability to trigger the 30-month automatic stay against a generic’s ANDA approval, meaning a generic can proceed toward market entry without waiting out litigation over that specific patent, even though the brand may still separately sue for infringement in district court. That distinction, between a patent’s existence and its procedural leverage, is the same category of gap the Hikma ruling illustrates on the enforcement side.<\/p>\n\n\n\n

    An Original Taxonomy: Four Questions No Patent Number Answers by Itself<\/h2>\n\n\n\n

    Across these two 2026 cases and the broader patent cliff data below, the same structural gap recurs in four distinct forms. This is DrugPatentWatch’s own framework for organizing them, not an established industry classification.<\/p>\n\n\n\n

    Type 1 \u2014 Enforceability Against Actual Conduct<\/h3>\n\n\n\n

    The patent record shows a valid, unexpired method-of-use patent. The open question is whether a specific competitor’s marketing, labeling, or sales conduct meets the current legal bar for inducement. Hikma v. Amarin<\/em> is the governing 2026 precedent.<\/p>\n\n\n\n

    The Conduct Standard After Jackson’s Opinion<\/h4>\n\n\n\n

    Post-Hikma<\/em>, the operative test asks whether conduct is affirmative and clear to the relevant audience, not whether a statement could theoretically be read as encouragement. That shifts the practical question from ‘does the patent exist’ to ‘what does the marketing file actually say,’ a question that requires reading sales materials, not patent claims.<\/p>\n\n\n\n

    Type 2 \u2014 Listing Validity<\/h3>\n\n\n\n

    The patent record shows a patent listed in the Orange Book. The open question is whether the patent actually claims the drug’s active ingredient, and survives an Amneal-style challenge or an FTC warning letter.<\/p>\n\n\n\n

    Devices vs. Drugs, After Amneal<\/h4>\n\n\n\n

    The Federal Circuit’s active-ingredient test in Teva v. Amneal<\/em> gives generic challengers and FTC staff a concrete, repeatable filter: pull the claims, check whether the active ingredient appears, and flag device-only claims as delisting candidates regardless of what a database’s expiration-date field says.<\/p>\n\n\n\n

    Type 3 \u2014 Economic Exposure Timing<\/h3>\n\n\n\n

    The patent record shows an expiration date. The open question is the actual, docket-adjusted date generic or biosimilar competition begins, once settlements, forfeiture triggers, and litigation timelines are accounted for.<\/p>\n\n\n\n

    Settlement Dates vs. Listed Expiration Dates<\/h4>\n\n\n\n

    A listed expiration date is a ceiling, not a forecast. The gap between the two is exactly what aggregate patent cliff estimates below have to approximate at the portfolio level, because no single field in a patent record carries a negotiated settlement date.<\/p>\n\n\n\n

    Type 4 \u2014 Portfolio Concentration Risk<\/h3>\n\n\n\n

    The patent record shows a drug’s total patent family size. The open question is how many of those patents are actually asserted or litigated, versus sitting unchallenged in the portfolio as untested defensive depth.<\/p>\n\n\n\n

    Litigated Patents vs. Total Portfolio<\/h4>\n\n\n\n

    A large family size can overstate defensive strength if most of the family has never been tested in litigation. It can equally understate risk if a small number of untested patents happen to be the ones a generic’s specific formulation or label actually implicates.<\/p>\n\n\n\n

    Type<\/th>Database Field<\/th>Strategic Question Left Open<\/th>2026 Example<\/th><\/tr><\/thead>
    1. Enforceability<\/td>Unexpired method-of-use patent, listed<\/td>Does this competitor’s actual marketing meet the inducement standard?<\/td>Hikma v. Amarin<\/td><\/tr>
    2. Listing validity<\/td>Patent listed in Orange Book<\/td>Does the patent actually claim the active ingredient?<\/td>Teva v. Amneal<\/td><\/tr>
    3. Timing<\/td>Listed expiration date<\/td>What is the actual, docket-adjusted generic-entry date?<\/td>Settlement-driven entry dates industry-wide<\/td><\/tr>
    4. Portfolio risk<\/td>Total patent family size<\/td>How many of those patents are actually litigated or assertable?<\/td>Concentrated blockbuster portfolios generally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    What the Patent Cliff Numbers Get Wrong Without This Layer<\/h2>\n\n\n\n

    The scale of the coming loss-of-exclusivity wave is not in serious dispute among the major forecasters, even though their headline numbers differ.<\/p>\n\n\n\n

    Why IQVIA, GlobalData, and Evaluate Don’t Agree on One Number<\/h3>\n\n\n\n

    IQVIA figures cited across industry coverage put the global patent cliff for innovative medicines through 2030 at more than $230 billion in current list-price value, with up to 65% of big pharma’s current revenue at risk. [14]<\/sup> GlobalData’s separately reported figure, also around $230 billion, is scoped to the US market specifically for 2025 to 2030. [16]<\/sup> Evaluate’s figure for the same 2025-to-2030 window exceeds $300 billion, because it is a global prescription-drug-revenue estimate rather than a US-only one. [15][16]<\/sup> The three numbers are measuring overlapping but not identical things, which is a methodology gap, not a disagreement about direction.<\/p>\n\n\n\n

    The $230B vs $300B+ Gap, Reconciled<\/h4>\n\n\n\n

    Once the scope difference is made explicit, US-only exposure clustering around $230 billion and global exposure clustering above $300 billion are consistent with each other, not competing estimates. A team citing one figure without the other’s scope caveat is presenting a partial number as if it were the whole picture, the same kind of gap this piece is built around, just applied to forecasting instead of litigation.<\/p>\n\n\n\n

    The Skinny-Label Variable Those Aggregate Numbers Don’t Carry<\/h3>\n\n\n\n

    None of the headline patent cliff figures break out how much of the at-risk revenue depends on method-of-use patents subject to a Hikma<\/em>-style skinny-label analysis, as opposed to composition-of-matter patents where the expiration date is close to determinative. That is a real limitation of the aggregate data: a $230 billion or $300 billion figure treats a clean compound-patent expiration and a contested, marketing-conduct-dependent method-of-use expiration as equivalent dollars, when the actual timing risk attached to each is very different.<\/p>\n\n\n\n

    What This Means for Brand Manufacturers<\/h2>\n\n\n\n

    Ballard Spahr’s guidance to brand clients after Hikma v. Amarin<\/em> is to tighten how method-of-use patents are drafted and prosecuted, and to reassess use-code descriptions and Orange Book listings so that patent claims map as closely as possible to the parts of a label a generic cannot avoid using. [4]<\/sup> That is a drafting and prosecution response to a litigation-standard problem, and it only becomes obvious once a team has separated ‘the patent exists’ from ‘the patent is enforceable against this generic’s actual conduct.’<\/p>\n\n\n\n

    Tightening Use-Code Descriptions and Orange Book Listings<\/h3>\n\n\n\n

    A use code drafted broadly enough to cover a drug’s entire indication is more exposed to a narrow-carve-out defense than one drafted to track the specific clinical claim a competitor cannot design around. Post-Hikma<\/em>, brand teams have a concrete incentive to audit existing use codes against this standard rather than treating the Orange Book listing as a one-time filing task.<\/p>\n\n\n\n

    What This Means for Generic and Biosimilar Manufacturers<\/h2>\n\n\n\n

    The ruling narrows, but does not eliminate, inducement exposure for a properly executed skinny label. Ballard Spahr’s analysis is explicit that the decision is not a blanket safe harbor: labeling, investor communications, and sales training still need to stay consistent with the approved carve-out, and marketing that strays into the still-patented use can reopen the door to a claim. [4]<\/sup><\/p>\n\n\n\n

    What a Clean Skinny Label Now Buys You<\/h3>\n\n\n\n

    What a generic manufacturer gains is a more predictable floor: ordinary distribution, equivalence statements, and FDA-required communications are, on their own, no longer enough for a brand to survive a motion to dismiss. That reduces the litigation-cost asymmetry that had made some companies hesitate to launch skinny-label products even with a facially clean carve-out in hand.<\/p>\n\n\n\n

    What This Means for Investors and Deal Teams<\/h2>\n\n\n\n

    An LOE model that treats a listed method-of-use patent’s expiration date as the generic-entry date, without separately weighting the litigation-conduct risk a Hikma<\/em>-style analysis introduces, is carrying a hidden assumption. That assumption became measurably safer for skinny-label generic entrants, and correspondingly less protective for the brand side, the moment the Court’s opinion issued on June 4, 2026.<\/p>\n\n\n\n

    A Worked Example: Pricing the Hikma Standard Into an LOE Model<\/h3>\n\n\n\n

    Consider two drugs with structurally identical method-of-use patent portfolios and identical listed expiration dates, five years out. Before June 4, 2026, a generic entrant weighing a skinny-label launch against either drug faced the same unresolved inducement-standard risk the Federal Circuit’s 2024 Amarin ruling had created. After the decision, that risk premium applies only to generics whose marketing plans actually reference the carved-out indication, not to the mere fact of a skinny-label launch. A model that hasn’t updated for that distinction is overpricing litigation risk on the generic side and underpricing it on any brand marketing that still leans on equivalence-to-patented-use messaging.<\/p>\n\n\n\n

    Methodology<\/h2>\n\n\n\n

    This analysis draws on the Supreme Court’s docket and opinion in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.<\/em>, No. 24-889, as tracked by SCOTUSblog and summarized by AIPLA and multiple law firm client alerts published between April and September 2026; Amarin Corporation’s own SEC filings (Form 10-K and 10-Q disclosures, 2020 through 2024) for the underlying litigation timeline; the Federal Circuit’s December 2024 opinion in Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC<\/em> as summarized by Cooley LLP and Haynes Boone; and FTC warning-letter coverage from IPWatchdog and Public Citizen tracking the agency’s Orange Book challenges from September 2023 through May 2025. Patent cliff figures are drawn from IQVIA-sourced industry reporting, GlobalData’s published US-market estimate, and Evaluate’s global World Preview estimate, all covering overlapping 2025-to-2030 windows with different geographic scope. The calculated 66-month litigation-duration figure is DrugPatentWatch’s own calculation from the November 30, 2020 complaint-filing date and the June 4, 2026 decision date, both drawn from primary sources. Forward-looking patent cliff estimates are industry projections, not confirmed events, and are labeled as such throughout.<\/p>\n\n\n\n

    Key Takeaways<\/h2>\n\n\n\n
      \n
    • On June 4, 2026, the Supreme Court ruled 9-0 in Hikma v. Amarin<\/em> that Hikma’s skinny-label marketing of generic Vascepa did not constitute induced patent infringement, reversing the Federal Circuit.<\/li>\n\n\n\n
    • The ruling changed the legal standard applied to marketing conduct, not the underlying patent record; Amarin’s method-of-use patents remain listed exactly as before.<\/li>\n\n\n\n
    • The dispute over whether Hikma’s conduct was lawful ran approximately 66 months, illustrating how long a patent-database entry can sit in strategic limbo even when the listing itself never changes.<\/li>\n\n\n\n
    • A structurally similar gap runs through Teva v. Amneal<\/em>: a patent can be listed in the Orange Book and still fail the Federal Circuit’s active-ingredient test for proper listing.<\/li>\n\n\n\n
    • The FTC’s Orange Book challenge campaign has grown to roughly 400 disputed listings since 2023, a number no static ‘patent listed’ field distinguishes from an untested one.<\/li>\n\n\n\n
    • Aggregate patent cliff estimates of $230 billion (US, IQVIA\/GlobalData) and $300 billion-plus (global, Evaluate) are consistent once scope is accounted for, but neither breaks out how much exposure depends on a Hikma<\/em>-style conduct analysis versus a fixed expiration date.<\/li>\n<\/ul>\n\n\n\n

      FAQ<\/h2>\n\n\n\n

      What did the Supreme Court decide in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.?<\/h3>\n\n\n\n

      On June 4, 2026, the Court held 9-0 that Amarin failed to plausibly allege induced patent infringement against Hikma, because Hikma’s skinny label, website statements, and press releases did not amount to affirmative, targeted conduct encouraging the patented use. The complaint was dismissed. [1][2]<\/sup><\/p>\n\n\n\n

      Did the ruling invalidate Amarin’s patents on Vascepa?<\/h3>\n\n\n\n

      No. The decision resolved whether Amarin’s complaint stated a valid legal claim for induced infringement, not whether the underlying method-of-use patents are valid. A separate, earlier ruling had already invalidated Amarin’s original MARINE-indication patents as obvious back in 2020. [7]<\/sup><\/p>\n\n\n\n

      What is a skinny label under the Hatch-Waxman Act?<\/h3>\n\n\n\n

      A skinny label lets a generic manufacturer omit a still-patented use from its FDA label while marketing the drug for the brand’s remaining, unpatented uses, under Section viii of the Hatch-Waxman Act.<\/p>\n\n\n\n

      What does a generic manufacturer now need to avoid inducement liability after Hikma v. Amarin?<\/h3>\n\n\n\n

      Keep FDA labeling, investor communications, and sales training aligned with the approved carve-out. The ruling does not create a blanket safe harbor; marketing materials, sales scripts, or payer decks that tie the product to the still-patented indication can still support a claim. [4]<\/sup><\/p>\n\n\n\n

      What did the Federal Circuit rule in Teva v. Amneal about Orange Book listings?<\/h3>\n\n\n\n

      In December 2024, the Federal Circuit affirmed that a patent must claim a drug’s active ingredient to be properly listed in the Orange Book, and upheld an order forcing Teva to delist five device-only patents covering its ProAir HFA inhaler. [10]<\/sup><\/p>\n\n\n\n

      How large is the pharmaceutical patent cliff between 2025 and 2030?<\/h3>\n\n\n\n

      Estimates vary by scope. IQVIA and GlobalData put US-market exposure at more than $230 billion through 2030. Evaluate’s global figure, which includes ex-US markets, exceeds $300 billion over roughly the same window. [14][15][16]<\/sup><\/p>\n\n\n\n

      How many Orange Book patent listings has the FTC challenged?<\/h3>\n\n\n\n

      Since its September 2023 policy statement, the FTC’s rounds of warning letters have grown the total number of challenged Orange Book listings to roughly 400, spanning inhalers, autoinjectors, and GLP-1 device patents. [12][13]<\/sup><\/p>\n\n\n\n

      Can a patent be valid and still not be enforceable against a specific competitor’s conduct?<\/h3>\n\n\n\n

      Yes. Hikma v. Amarin<\/em> is a direct illustration: the Court did not question whether Amarin’s method-of-use patents could ever be infringed, only whether Hikma’s specific conduct met the legal bar for inducement. Validity and enforceability against this conduct are separate questions.<\/p>\n\n\n\n

      What is the difference between a patent database and patent strategy intelligence?<\/h3>\n\n\n\n

      A patent database answers what exists: patent numbers, assignees, expiration dates, and listing status. Strategy intelligence answers what a company can do about it: whether a listing is defensible, whether marketing conduct creates litigation risk, and what the actual, docket-adjusted timeline for generic entry looks like. DrugPatentWatch’s own data and litigation tracking are built around closing that second gap, not just the first.<\/p>\n\n\n\n

      Why did a unanimous 9-0 Supreme Court ruling matter more than a split decision would have?<\/h3>\n\n\n\n

      A unanimous, single-opinion ruling on a legal standard leaves little room for lower courts to read exceptions into it. Patent counsel treat 9-0 opinions as a firmer baseline for advising clients than a 5-4 or 6-3 split, which invites relitigation of the boundary.<\/p>\n\n\n\n

      References<\/h2>\n\n\n\n
        \n
      1. SCOTUSblog. (2026). Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.<\/em>, Docket No. 24-889. https:\/\/www.scotusblog.com\/cases\/hikma-pharmaceuticals-usa-inc-v-amarin-pharma-inc\/<\/li>\n\n\n\n
      2. American Intellectual Property Law Association. (2026, June 4). Supreme Court Issues Unanimous Decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. https:\/\/www.aipla.org\/detail\/news\/2026\/06\/04\/supreme-court-issues-unanimous-decision-in-hikma-pharmaceuticals-usa-inc.-v.-amarin-pharma–inc<\/li>\n\n\n\n
      3. Faegre Drinker. (2026, June 4). Supreme Court Decides Hikma Pharmaceuticals v. Amarin Pharma. https:\/\/www.faegredrinker.com\/zh\/insights\/publications\/2026\/6\/supreme-court-decides-hikma-pharmaceuticals-v-amarin-pharma<\/li>\n\n\n\n
      4. Shryock, T. (2026, September 17). Generic drugs get a legal boost from Supreme Court ruling, law firm analysis finds. Medical Economics<\/em>. https:\/\/www.medicaleconomics.com\/view\/generic-drugs-get-a-legal-boost-from-supreme-court-ruling-law-firm-analysis-finds<\/li>\n\n\n\n
      5. Reed, T. (2026, April 29). Supreme Court takes up generic drug labeling fight. Axios<\/em>. https:\/\/www.axios.com\/2026\/04\/29\/supreme-court-generic-drug-labeling-fight<\/li>\n\n\n\n
      6. Hikma Pharmaceuticals PLC. (2026, June 4). Hikma comments on Supreme Court of the United States’ unanimous decision in favour of Hikma. https:\/\/www.hikma.com\/news\/hikma-comments-on-supreme-court-of-the-united-states-unanimous-decision-in-favour-of-hikma\/<\/li>\n\n\n\n
      7. Amarin Corporation PLC. (2021). Form 10-K, fiscal year 2020. U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/897448\/000156459021008382\/amrn-10k_20201231.htm<\/li>\n\n\n\n
      8. Amarin Corporation PLC. (2022). Form 10-K exhibit (XBRL). U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/897448\/000095017022002401\/R7.htm<\/li>\n\n\n\n
      9. Amarin Corporation PLC. (2024). Form 10-K exhibit (XBRL). U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/897448\/000095017024022636\/R7.htm<\/li>\n\n\n\n
      10. Cooley LLP. (2025, January 2). Teva v. Amneal Ruling Interprets Orange Book Listing Statute, Affirms Delisting of Device Patents. https:\/\/www.cooley.com\/news\/insight\/2025\/2025-01-02-teva-v-amneal-ruling-interprets-orange-book-listing-statute-affirms-delisting-of-device-patents<\/li>\n\n\n\n
      11. Pelletier, B. (2025, March 13). Teva v. Amneal: Reshaping Generic Drug Rights. Haynes Boone. https:\/\/www.haynesboone.com\/news\/publications\/teva-v-amneal-reshaping-generic-drug-rights<\/li>\n\n\n\n
      12. IPWatchdog. (2025, May 22). FTC Renews Campaign to Remove ‘Junk’ Inhaler and Device Patents from Orange Book Listings. https:\/\/ipwatchdog.com\/2025\/05\/22\/ftc-renews-campaign-remove-junk-inhaler-device-patents-orange-book-listings\/<\/li>\n\n\n\n
      13. Public Citizen. (2024, April 30). FTC Right to Challenge Junk Patent Listings. https:\/\/commondreams.org\/newswire\/ftc-right-to-challenge-junk-patent-listings<\/li>\n\n\n\n
      14. PM Live \/ Pharmafile. Launching into an AI-powered future: a prescription for success (IQVIA patent cliff data). https:\/\/pmlive.com\/intelligence\/launching-into-an-ai-powered-future-a-prescription-for-success\/<\/li>\n\n\n\n
      15. Evaluate Ltd. Portfolio Tactics to Scale the $300bn Patent Cliff. https:\/\/www.evaluate.com\/thought-leadership\/portfolio-tactics-to-scale-the-300bn-patent-cliff\/<\/li>\n\n\n\n
      16. IntuitionLabs. (2026, September 5). Drug Patent Expirations 2027-2030: Market Entry Calendar. https:\/\/intuitionlabs.ai\/pdfs\/drug-patent-expirations-2027-2030-calendar.pdf<\/li>\n\n\n\n
      17. Hollan, M. (2026, June 2). The Pharma Patent Cliff Explained: What It Is and How Companies Navigate It. PharmExec<\/em>. https:\/\/www.pharmexec.com\/view\/patent-cliff-explained-what-how-companies-navigate<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

        On June 4, 2026, the Supreme Court ruled 9-0 that Hikma Pharmaceuticals did not induce patent infringement by selling a […]<\/p>\n","protected":false},"author":1,"featured_media":39700,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39699","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39699"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39699\/revisions"}],"predecessor-version":[{"id":39701,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39699\/revisions\/39701"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39700"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}